Skip to content

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Adjuvanted Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02882100
Enrollment
823
Registered
2016-08-29
Start date
2016-04-30
Completion date
2023-01-25
Last updated
2023-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza, Influenza-like Illness

Keywords

influenza, vaccine, vaccination, nursing home, cluster randomized trial, respiratory-related hospitalization

Brief summary

This study is powered to prospectively evaluate the relative effectiveness of adjuvanted trivalent influenza vaccine (aTIV; FLUAD) in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the commercially available, standard dose trivalent seasonal influenza vaccine (TIV; Fluvirin).

Detailed description

SUMMARY: A random study sample of up to 1000 NHs within 75 miles of the local area of the 121 cities where the CDC performs weekly influenza surveillance (estimated N= 11,239) may be offered the opportunity for participation; the first 1000 eligible to participate and accepting the offer will be enrolled. Participating facilities will be offered vaccine education for residents and staff, but will be randomly allocated to receive aTIV (FLUAD) vaccine or usual care (TIV) vaccination for their residents. BACKGROUND: Lower respiratory tract infection (LRI), including pneumonia, bronchitis, and tracheobronchitis, is the leading cause of infectious mortality and hospitalization in older adults , and nursing home (NH) residents. Pneumonia and infection often produce attenuated signs and symptoms in older adults, leading to delayed or even misdiagnosis for this population. Diagnosis is further compromised due to few and sporadic clinician visits with nursing home residents, and reduced access to radiology. LRI may or may not directly lead to hospitalization, but LRIs are associated with considerable other morbidity than can result in hospitalization, including exacerbation of underlying cardiopulmonary diseases. Hospitalization rates for NH residents vary considerably between facilities, but the majority of hospitalizations occur during the 12 weeks during which influenza peaks each year. OBJECTIVES: The primary objective is to estimate the differences in hospitalization rates during influenza season experienced by long-stay nursing home residents, between facilities using adjuvanted trivalent vaccine vs. standard trivalent vaccine. The secondary objective is to estimate the differences in the likelihood of Activities of Daily Living (ADL) functional decline and mortality rates in the study nursing homes, and influenza outbreaks.

Interventions

BIOLOGICALadjuvanted trivalent influenza vaccine

Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).

BIOLOGICALtrivalent influenza vaccine

Nursing home residents are allocated to receive standard trivalent vaccine (TIV).

Sponsors

Case Western Reserve University
CollaboratorOTHER
Brown University
CollaboratorOTHER
Seqirus
CollaboratorINDUSTRY
Insight Therapeutics, LLC
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Long-term care facilities within 75 miles of one of the 121 cities that serve as CDC surveillance sites

Exclusion criteria

* Facilities that used high dose influenza vaccine in residents over age 65 in previous influenza season (2015-16) * Facilities having fewer than 50 long-stay residents * Hospital-based facilities * Facilities with more than 20% of the population under age 65 * Facilities not submitting Minimum Data Set (MDS) data

Design outcomes

Primary

MeasureTime frameDescription
Hospitalization for a respiratory-related Illnessup to 1 yearTime to first occurrence of hospitalization for a respiratory-related Illness based upon Medicare inpatient hospital claims
Hospitalization for all causesup to 1 yearTime to first occurrence of hospitalization for all-causes

Secondary

MeasureTime frameDescription
Activities of daily living (ADL) scoresup to 1 yearChange in activities of daily living (ADL) scores
Mortalityup to 1 yearDifference in mortality rate

Other

MeasureTime frameDescription
Influenza outbreaksup to 1 yearDifference in occurrence of documented influenza outbreaks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026